Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study

Abstract

Lipid management strategies in Europe during the study period were dominated by statin monotherapy. Even after prolonged follow-up on lipid-modifying therapy, approximately 60% of Europeans studied did not achieve guideline recommended cholesterol goals. Future emphasis must be placed on subsequent lipid panel monitoring, as well as the use of more efficacious, well-tolerated lipid-modifying therapies such as dual cholesterol inhibitors to enable more European patients to attain their recommended cholesterol goals.

Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis

“…Antihypertensive medication is prescribed in only 25% to 50% of cases of hypertension in North America and Europe (19), and global rates of hypertension control to Ͻ140/90 mm Hg range from only 5.4% in Korea to 58% in Barbados (20). The management of LDL-C remains suboptimal even in patients at high cardiovascular risk, with only 40% to 50% of patients achieving LDL-C targets in the U.S. (21) and Europe (22).…”

LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results

“…Observational studies 4,14,15,17 have shown that patients are often treated suboptimally, leading to an increased cardiovascular event rate 14,16 . Suboptimal treatment is often the result of failure to titrate to goal attainment 18 .…”

Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions

“…[26][27][28][29][30][31][32][33][34][35] However, some studies were focused on the control of a single risk factor (blood pressure or lipids) and there is limited comparable information on management and control of CVD risk factors in patients at high CVD risk across…”